Circulating tumor cells in pancreatic cancer patients: Methods of detection and clinical implications

International Journal of Cancer

Volumn 134, Issue 1, 2014, Pages 1-8

  Tjensvoll, Kjersti ^a   Nordgård, Oddmund ^a   Smaaland, Rune ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

circulating tumor cells; pancreatic adenocarcinoma; pancreatic cancer; prognosis; survival

Indexed keywords

BACULOVIRAL INHIBITOR OF APOPTOSIS REPEAT CONTAINING 5; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 5; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN 8; CYTOKERATIN AE1; CYTOKERATIN AE3; CYTOKERATIN ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE; GLYCOPROTEIN; MUCIN 1; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ADNATEST; CANCER PATIENT; CANCER PROGNOSIS; CANCER TEST; CELLSEARCH SYSTEM; CIRCULATING TUMOR CELL; CTC CHIP; DENSITY GRADIENT CENTRIFUGATION; EPITHELIAL IMMUNOSPOTTING; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOLOGICAL CAPTURE TECHNIQUE; ISOLATION BY SIZE OF EPITHELIAL TUMOR; MEMBRANE FILTER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SURVIVAL TIME;

CIRCULATING TUMOR CELLS; PANCREATIC ADENOCARCINOMA; PANCREATIC CANCER; PROGNOSIS; SURVIVAL;

DISEASE PROGRESSION; HUMANS; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885956968     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28134     Document Type: Review

References (72)

1. Blackford A, Parmigiani G, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 2009; 69: 3681-88.
2. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011; 378: 607-20.
3. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual, 7th ed. New York: Springer, 2010.
4. Halm U, Schumann T, Schiefke I, et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82: 1013-6.
5. Katz A, Hanlon A, Lanciano R, et al. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41: 393-6.
6. Mehta J, Prabhu R, Eshpuniyani P, et al. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies. Trop Gastroenterol 2010; 31: 190-4.
7. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
8. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet 2004; 363: 1049-57.
9. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
10. Hidalgo M,. Pancreatic cancer. N Engl J Med 2010; 362: 1605-17.
11. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-Paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29: 4548-54.
12. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25.
13. Tada M, Omata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53: 2472-4.
14. Balic A, Dorado J, Alonso-Gomez M, et al. Stem cells as the root of pancreatic ductal adenocarcinoma. Exp Cell Res 2011; 318: 691-704.
15. Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012; 142: 730-33.
16. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545-54.
17. Shibata D, Almoguera C, Forrester K, et al. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 1990; 50: 1279-83.
18. Aktas B, Tewes M, Fehm T, et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009; 11: R46.
19. Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68.
20. Pantel K, Brakenhoff RH,. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448-56.
21. Polyak K, Weinberg RA,. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-73.
22. Stoecklein NH, Klein CA,. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer 2010; 126: 589-98.
23. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002; 360: 683-9.
24. Powell AA, Talasaz AH, Zhang H, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012; 7: e33788.
25. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-26.
26. Alix-Panabieres C, Schwarzenbach H, Pantel K,. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012; 63: 199-215.
27. Fidler IJ,. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 1970; 45: 773-82.
28. Gupta PB, Mani S, Yang J, et al. The evolving portrait of cancer metastasis. Cold Spring Harb Symp Quant Biol 2005; 70: 291-7.
29. Cen P, Ni X, Yang J, et al. Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta 2012; 1826: 350-6.
30. Paez D, Labonte MJ, Bohanes P, et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 2012; 18: 645-53.
31. Uhr JW, Pantel K,. Controversies in clinical cancer dormancy. Proc Natl Acad Sci USA 2011;108: 12396-400.
32. Dean M, Fojo T, Bates S,. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-84.
33. Xenidis N, Ignatiadis M, Apostolaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009; 27: 2177-84.
34. Ignatiadis M, Xenidis N, Perraki M, et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 2007; 25: 5194-202.
35. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-30.
36. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91.
37. Xenidis N, Perraki M, Kafousi M, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006; 24: 3756-62.
38. Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011; 29: 1547-55.
39. Soeth E, Grigoleit U, Moellmann B, et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol 2005; 131: 669-76.
40. Zhou J, Hu L, Yu Z, et al. Marker expression in circulating cancer cells of pancreatic cancer patients. J Surg Res 2011; 171: 631-6.
41. Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000; 156: 57-63.
42. Zheng S, Lin H, Liu JQ, et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A 2007; 1162: 154-61.
43. Zheng S, Lin HK, Lu B, et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdev 2011; 13: 203-13.
44. Lin HK, Zheng S, Williams AJ, et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010; 16: 5011-8.
45. Williams A, Balic M, Datar R, et al. Size-Based Enrichment Technologies for CTC Detection and Characterization. Recent Results Cancer Res 2012; 195: 87-95.
46. Xu T, Lu B, Tai YC, et al. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res 2010; 70: 6420-6.
47. Bhagat AA, Hou HW, Li LD, et al. Pinched flow coupled shear-modulated inertial microfluidics for high-throughput rare blood cell separation. Lab Chip 2011; 11: 1870-8.
48. Parkinson DR, Dracopoli N, Gumbs Petty B, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 2012; 10: 138.
49. Neurauter AA, Bonyhadi M, Lien E, et al. Cell isolation and expansion using Dynabeads. Adv Biochem Eng Biotechnol 2007; 106: 41-73.
50. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-9.
51. Talasaz AH, Powell AA, Huber DE, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 2009; 106: 3970-5.
52. Gascoyne PR, Noshari J, Anderson TJ, et al. Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 2009; 30: 1388-98.
53. Gleghorn JP, Pratt ED, Denning D, et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010; 10: 27-9.
54. Sheng W, Chen T, Kamath R, et al. Aptamer-enabled efficient isolation of cancer cells from whole blood using a microfluidic device. Anal Chem 2012; 84: 4199-206.
55. Sieuwerts AM, Kraan J, Bolt J, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009; 101: 61-6.
56. Hsieh HB, Marrinucci D, Bethel K, et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006; 21: 1893-9.
57. Krivacic RT, Ladanyi A, Curry DN, et al. A rare-cell detector for cancer. Proc Natl Acad Sci USA 2004; 101: 10501-4.
58. Miller MC, Doyle GV, Terstappen LW,. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010; 2010: 617421.
59. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-904.
60. Kurihara T, Itoi T, Sofuni A, et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg 2008; 15: 189-95.
61. Khoja L, Backen A, Sloane R, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer 2011; 106: 508-16.
62. Alix-Panabieres C, Vendrell JP, Pelle O, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007; 53: 537-9.
63. Tjensvoll K, Oltedal S, Farmen RK, et al. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. Clin Breast Cancer 2010; 10: 378-84.
64. Hoffmann K, Kerner C, Wilfert W, et al. Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J Gastroenterol 2007; 13: 257-63.
65. Sergeant G, Roskams T, van Pelt J, et al. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma. BMC Cancer 2011; 11: 47.
66. de Albuquerque A, Kubisch I, Breier G, et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology 2012; 82: 3-10.
67. Chausovsky G, Luchansky M, Figer A, et al. Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung. Cancer 1999; 86: 2398-405.
68. Ren C, Han C, Zhang J, et al. Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy. Cancer Biol Ther 2011; 12: 700-6.
69. Marrinucci D, Bethel K, Kolatkar A, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012; 9: 016003.
70. Pachmann K, Camara O, Kavallaris A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008; 26: 1208-15.
71. Z'Graggen K, Centeno BA, Fernandez-del Castillo C, et al. Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. Surgery 2001; 129: 537-46.
72. Mataki Y, Takao S, Maemura K, et al. Carcinoembryonic antigen messenger RNA expression using nested reverse transcription-PCR in the peripheral blood during follow-up period of patients who underwent curative surgery for biliary-pancreatic cancer: longitudinal analyses. Clin Cancer Res 2004; 10: 3807-14.